Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.62 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.62 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.62 |
| ▸ | CD69 | Q07108 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 2/20 | 0.51 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144324 | 1.00 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL30654785 | 1.00 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL4809869 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL9566048 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL29454030 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL9566045 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL9566182 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL4809860 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL8516937 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL16298755 | 0.97 | CD69 (0.61) | LGALS3LGALS8LGALS4CD69ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250270319-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250145709-A1 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-3368575-B1 | ANTI-SIGLEC-9 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12258398-B2 | Anti-Siglec-5 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12247073-B2 | Anti-CD33 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-12227568-B2 | Anti-Siglec-7 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240329054-A1 | SOLUBLE CD33 AS A BIOMARKER FOR ANTI-CD33 EFFICACY | ALECTOR LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-11667710-B2 | Anti-Siglec-9 antibodies and methods of use thereof | ALECTOR LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4149625-A2 | TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS | Viratides, LLC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230035072-A1 | METHODS OF USE OF ANTI-CD33 ANTIBODIES | ALECTOR LLC (US) | 2023-02-02 | — | — | US | disclosed |
| US-20220411503-A1 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220315656-A1 | ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220281976-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220251190-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11390680-B2 | Anti-Siglec-7 antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220162309-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-11254743-B2 | Anti-CD33 antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | LGALS3 236/4885LGALS8 242/4885LGALS4 287/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | LGALS3 77/4885LGALS8 34/4885LGALS4 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.